Clinical Trial Update: Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids [NA]

View source ↗

Summary

A terminated clinical trial evaluated Efalizumab for graft-versus-host disease of the skin that did not respond to steroids, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Efalizumab (efalizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Graft Versus Host Disease | NA | Status: TERMINATED | Results posted: 2017-04-06